SCHEMBL31464433

SCHEMBL31464433

O=C(c1ccc(-c2ccc3c(Cl)ccnc3c2)c(F)c1)N1CCCCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 1/20 0.51
HPGD P15428 10/20 0.49
KCNH2 Q12809 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47
GRM2 Q14416 2/20 0.46
MGLL Q99685 1/20 0.44
CNR1 P21554 1/20 0.44
MAPT P10636 2/20 0.43
MAPK1 P28482 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MEN1 O00255 1/20 0.43
STAT3 P40763 1/20 0.43
KMT2A Q03164 1/20 0.43
FASN P49327 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
GLA P06280 1/20 0.42
TSHR P16473 1/20 0.42
RORC P51449 1/20 0.41
ADORA2A P29274 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31464521 0.99 SMYD3 (0.52) SMYD3HPGDKCNH2HRH3GRM2
SCHEMBL31464497 0.92 HPGD (0.52) SMYD3HPGDKCNH2HRH3GRM2
SCHEMBL31464356 0.91 HPGD (0.50) SMYD3HPGDKCNH2HRH3GRM2
SCHEMBL31464394 0.90 SMYD3 (0.49) SMYD3HPGDGRM2MGLLMAPT
SCHEMBL31464757 0.85 SMYD3 (0.56) SMYD3MGLLMAPTMAPK1SMN1; SMN2
SCHEMBL31464635 0.84 SMYD3 (0.44) SMYD3HRH3MGLLMAPTMAPK1
SCHEMBL4150653 0.84 SMYD3 (0.66) SMYD3HPGDMAPTMAPK1SMN1; SMN2
SCHEMBL31464392 0.84 HPGD (0.47) SMYD3HPGDKCNH2HRH3MAPT
SCHEMBL31464605 0.84 SMYD3 (0.48) SMYD3KCNH2HRH3MGLLMAPT
SCHEMBL31464602 0.82 PKM (0.48) SMYD3HPGDGRM2MGLLMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025064853-A1 RIPK3 INHIBITORS AND METHODS OF USE Momentum Therapeutics, Inc. (US) 2025-03-27 WO disclosed
US-20250092031-A1 RIPK3 INHIBITORS AND METHODS OF USE INTEGRAL BIOSCIENCES PVT. LTD. (IN) 2025-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250092031-A1 RIPK3 INHIBITORS AND METHODS OF USE RIPK3, RIPK1, RIPK2 SMYD3 1845/4885HPGD 3528/4885KCNH2 4664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.